The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iakovleva O.V.

Russian Medical Academy of Continuous Professional Education, Centre of Extrapyramidal Disorders, Moscow, Russsia

Liashenko E.A.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva;
Tsentr kstrapiramidnykh zabolevaniĭ, Moskva

Poluéktov M.G.

Kurs somnologii pri kafedre nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Dysfunction of the orexin system in Parkinson’s disease

Authors:

Iakovleva O.V., Liashenko E.A., Poluéktov M.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2): 82‑89

DOI: 10.17116/jnevro201811806282

Read: 6978 times

Download PDF (RU)
Contact the author
Table of contents

DYSFUNCTION OF THE OREXIN SYSTEM IN PARKINSON’S DISEASE
DYSFUNCTION OF THE OREXIN SYSTEM IN PARKINSON’S DISEASE

To cite this article:

Iakovleva OV, Liashenko EA, Poluéktov MG. Dysfunction of the orexin system in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2):82‑89. (In Russ.)
https://doi.org/10.17116/jnevro201811806282

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Traditionally, Parkinson’s disease (PD) is associated with the lesion of the substantia nigra and dopamine system dysfunction. However, current studies show the involvement of other CNS regions, which extend far beyond the substantia nigra, in the pathogenesis of PD. The prevalence of altered α-synuclein in PD leads to the dysfunction of several neurotransmitter systems including the orexin system located in the hypothalamus. The involvement of this system in the neurodegenerative process explains some symptoms of PD including daily drowsiness and eating disorders. The authors consider the pathophysiology of the orexin system and its role in the pathogenesis of PD.

Keywords:

Parkinson’s disease
pathogenesis
orexin system

Authors:

Iakovleva O.V.

Russian Medical Academy of Continuous Professional Education, Centre of Extrapyramidal Disorders, Moscow, Russsia

Liashenko E.A.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva;
Tsentr kstrapiramidnykh zabolevaniĭ, Moskva

Poluéktov M.G.

Kurs somnologii pri kafedre nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Close metadata

References:

  1. Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, Tafuri D, Salerno M, Filippi N, Nuccio F, Ruberto M, De Luca V, Cipolloni L, Cibelli G, Mollica MP, Iacono D, Nigro E, Monda M, Messina G, Messina A. Orexin System: The Key for a Healthy Life. Frontiers in Physiology. 2017;8:357. https://doi.org/10.3389/fphys.2017.00357
  2. Siegel J. Hypocretin (OREXIN): Role in Normal Behavior and Neuropathology. Annual Review of Psychology. 2004;55(1):125-148. https://doi.org/10.1146/annurev.psych.55.090902.141545
  3. Schöne C, Burdakov D. Orexin/Hypocretin and Organizing Principles for a Diversity of Wake-Promoting Neurons in the Brain. Curr Top Behav Neurosci. 2017;33:51-74. https://doi.org/10.1007/7854_2016_45
  4. Scammell T. Narcolepsy. New England Journal of Medicine. 2015;373(27):2654-2662. https://doi.org/10.1056/nejmra1500587
  5. España RA, Scammell TE. Sleep Neurobiology from a Clinical Perspective. Sleep. 2011;34(7):845-858. https://doi.org/10.5665/SLEEP.1112
  6. Dauvilliers Y, Jennum P, Plazzi G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Medicine. 2013;14(8):775-781. https://doi.org/10.1016/j.sleep.2012.10.006
  7. Flores Á, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Frontiers in Neuroscience. 2013;7:256. https://doi.org/10.3389/fnins.2013.00256
  8. Kok S, Overeem S, Visscher T, Lammers GJ, Seidell JC, Pijl H, Meinders AE. Hypocretin Deficiency in Narcoleptic Humans Is Associated with Abdominal Obesity. Obesity Research. 2003;11(9):1147-1154. https://doi.org/10.1038/oby.2003.156
  9. Zhao X, Zhang R, Tang S, Xuan Zhao; Rui Xue Zhang; Shi Tang; Ren YY, Yang WX, Liu XM, Tang JY. Orexin-A-induced ERK1/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis. Peptides. 2014;54:140-147. https://doi.org/10.1016/j.peptides.2013.11.019
  10. Wayner M, Armstrong D, Phelix C, Oomura Y. Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides. 2004;25(6):991-996. https://doi.org/10.1016/j.peptides.2004.03.018
  11. Hu B, Yang N, Qiao Q, Hu Z, Zhang J. Roles of the orexin system in central motor control. Neuroscience & Biobehavioral Reviews. 2015;49:43-54. https://doi.org/10.1016/j.neubiorev.2014.12.005
  12. Xue Y, Yang Y, Liu H Chen WF, Chen AQ, Sheng Q, Chen XY, Wang Y, Chen H, Liu HX, Pang YY and Chen L. Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats. European Journal of Neuroscience. 2016;44(5):2247-2257. https://doi.org/10.1111/ejn.13323
  13. Sheng Q, Xue Y, Wang Y Chen A , Liu C, Liu Y, Chen L. The Subthalamic Neurons are Activated by Both Orexin-A and Orexin-B. Neuroscience. 2018;369:97-108. https://doi.org/10.1016/j.neuroscience.2017.11.008
  14. Hrabovszky E, Molnár C, Borsay B, Gergely P, Herczeg L, Liposits Z. Orexinergic Input to Dopaminergic Neurons of the Human Ventral Tegmental Area. PLoS ONE. 2013;8(12):83029. https://doi.org/10.1371/journal.pone.0083029
  15. Di Sebastiano A, Coolen L. Orexin and natural reward. Progress in Brain Research. 2012;65-77. https://doi.org/10.1016/b978-0-444-59489-1.00006-9
  16. Bensaid M, Tandé D, Fabre V, Michel P, Hirsch E, François C. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques. European Journal of Neuroscience. 2014;41(1):129-136. https://doi.org/10.1111/ejn.12761
  17. Korotkova T, Eriksson K, Haas H, Brown R. Selective excitation of GABAergic neurons in the substantia nigra of the rat by orexin/hypocretin in vitro. Regulatory Peptides. 2002;104(1-3):83-89. https://doi.org/10.1016/s0167-0115(01)00323-8
  18. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, Brown RE. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci. 2003;23(1):7-11.
  19. Toulorge D, Guerreiro S, Hild A, et al. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. The FASEB Journal. 2011;25(8):2563-2573. https://doi.org/10.1096/fj.11-182824
  20. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130:1577-1585. https://doi.org/10.1016/j.neurobiolaging.2011.03.014
  21. Thannickal T, Lai Y, Siegel J. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130(6):1586-1595. https://doi.org/10.1093/brain/awm097
  22. Christine C, Marks W, Ostrem J. Development of Parkinson’s disease in patients with Narcolepsy. Journal of Neural Transmission. 2012;119(6):697-699. https://doi.org/10.1007/s00702-011-0761-z
  23. Yuan L, Dong H, Zhang H, Zhao R; Gong G, Chen X, Zhang L, Xiong L. Neuroprotective Effect of Orexin-A Is Mediated by an Increase of Hypoxia-inducible Factor-1 Activity in Rat. Anesthesiology. 2011;114(2):340-354. https://doi.org/10.1097/aln.0b013e318206ff6f
  24. Semenza G. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends in Molecular Medicine. 2001;7(8):345-350. https://doi.org/10.1016/s1471-4914(01)02090-1
  25. Weinreb O, Mandel S, Youdim M, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radical Biology and Medicine. 2013;62:52-64. https://doi.org/10.1016/j.freeradbiomed.2013.01.017
  26. Khan M, Khan H, Singh I, Singh A. Hypoxia inducible factor-1 alpha stabilization for regenerative therapy in traumatic brain injury. Neural Regeneration Research. 2017;12(5):696. https://doi.org/10.4103/1673-5374.206632
  27. Feng Y, Liu T, Li X, Liu Y, Zhu X, Jankovic J, Pan T, Wu Y. Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson’s disease. Neuroscience Letters. 2014;579:35-40. https://doi.org/10.1016/j.neulet.2014.07.014
  28. Hadadianpour Z, Fatehi F, Ayoobi F, Kaeidi A, Shamsizadeh A, Fatemi I. The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson’s disease. Neurological Research. 2017;39(9):845-851. https://doi.org/10.1080/01616412.2017.1352185
  29. Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch E, Michel P. The Sleep-Modulating Peptide Orexin-B Protects Midbrain Dopamine Neurons from Degeneration, Alone or in Cooperation with Nicotine. Molecular Pharmacology. 2014;87(3):525-532. https://doi.org/10.1124/mol.114.095703
  30. Braak H, Tredici K, Rüb U, de Vos R, Jansen Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197-211. https://doi.org/10.1016/s0197-4580(02)00065-9
  31. Selikhova M, Williams D, Kempster P, Holton J, Revesz T, Lees A. A clinico-pathological study of subtypes in Parkinson’s disease. Brain. 2009;132(11):2947-2957. https://doi.org/10.1093/brain/awp234
  32. Marras C, Chaudhuri K. Nonmotor features of Parkinson’s disease subtypes. Movement Disorders. 2016;31(8):1095-1102. https://doi.org/10.1002/mds.26510
  33. Sauerbier A, Rosa-Grilo M, Qamar M, Chaudhuri K. Nonmotor Subtyping in Parkinson’s Disease. International Review of Neurobiology. 2017:447-478. https://doi.org/10.1016/bs.irn.2017.05.011
  34. Ylikoski A, Martikainen K, Sarkanen T, Partinen M. Parkinson’s disease and narcolepsy-like symptoms. Sleep Medicine. 2015;16(4):540-544. https://doi.org/10.1016/j.sleep.2014.12.010
  35. Sauerbier A, Jenner P, Todorova A, Chaudhuri K. Non motor subtypes and Parkinson’s disease. Parkinsonism & Related Disorders. 2016;22:41-46. https://doi.org/10.1016/j.parkreldis.2015.09.027
  36. Bliwise D, Trotti L, Juncos J, Factor S, Freeman A, Rye D. Daytime REM sleep in Parkinson’s disease. Parkinsonism & Related Disorders. 2013;19(1):101-103. https://doi.org/10.1016/j.parkreldis.2012.08.003
  37. Bril A, Perez-Lloret S, Rossi M, Morisset P, Sorrentino L, Iglesias M, Escobar AM, Vernetti PM, Cerquetti D, Merello M, Fariña S. A multifactorial study on nutritional status, binge eating and physical activity as main factors directly influencing body weight in Parkinson’s disease. J npj Parkinson’s Disease. 2017;3(1). https://doi.org/10.1038/s41531-017-0018-0
  38. Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol. 2003;5(2):149-160.
  39. Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2(11):669-676. https://doi.org/10.1016/s1474-4422(03)00555-6
  40. Matsumura K, Tsuchihashi T, Abe I. Central orexin-A augments sympathoadrenal outflow in conscious rabbits. Hypertension. 2001;37(6):1382-1387. https://doi.org/10.1161/01.hyp.37.6.1382
  41. Kayaba Y, Nakamura A, Kasuya Y. Attenuated defense response and low basal blood pressure in orexin knockout mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(3):581-593. https://doi.org/10.1152/ajpregu.00671.2002.
  42. Frucht S, Rogers J, Greene P, Gordon M, Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908-1908. https://doi.org/10.1212/wnl.52.9.1908
  43. Paus S, Brecht H, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Movement Disorders. 2003;18(6):659-667. https://doi.org/10.1002/mds.10417
  44. Monti J, Hawkins M, Jantos H, D’Angelo L, Fernandez M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology. 1988;95(3):395-400. https://doi.org/10.1007/bf00181955
  45. Brodsky M, Godbold J, Roth T, Olanow C. Sleepiness in Parkinson’s disease: A controlled study. Movement Disorders. 2003;18(6):668-672. https://doi.org/10.1002/mds.10429
  46. Razmy A, Lang A, Shapiro C. Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. Archives of Neurology. 2004;61(1): 97. https://doi.org/10.1001/archneur.61.1.97
  47. Michinaga S, Hisatsune A, Isohama Y, Katsuki H. An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture. Neuroscience Research. 2010;68(4):315-321. https://doi.org/10.1016/j.neures.2010.08.005
  48. Zeng J, Wei M, Li T, Chen W, Feng Y, Shi R, Song Y, Zheng W, Ma W. Risk of Obstructive Sleep Apnea in Parkinson’s Disease: A Meta-Analysis. PLoS ONE. 2013;8(12):82091. https://doi.org/10.1371/journal.pone.0082091
  49. Diederich N, Vaillant M, Leischen M, Mancuso G, Golinval S, Nati R, Schlesser M. Sleep apnea syndrome in Parkinson’s disease. A case-control study in 49 patients. Movement Disorders. 2005;20(11):1413-1418. https://doi.org/10.1002/mds.20624
  50. Seyer-Hansen K. Postprandial hypotension. BMJ. 1977;2(6097):1262-1262. https://doi.org/10.1136/bmj.2.6097.1262
  51. Swick T. Parkinson’s Disease and Sleep/Wake Disturbances. Parkinson’s Disease. 2012;2012:1-14. https://doi.org/10.1155/2012/205471
  52. Babkina OV, Poluektov MG, Levin OS. The heterogeneity of daytime sleepiness in Parkinson’s disease. Zhurnal Nevrologii I Psikhiatrii im. S.S. Korsakova. 2016;111:(6):60-70. (In Russ.) https://doi.org/10.17116/jnevro20161166260-70
  53. Sutton EL. Profile of suvorexant in the management of insomnia. Drug Design, Development and Therapy. 2015;9:6035-6042. https://doi.org/10.2147/DDDT.S73224
  54. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. European Journal of Neurology. 2012;20(1):5-15. https://doi.org/10.1111/j.1468-1331.2012.03866.x
  55. Rodrigues T, Castro Caldas A, Ferreira J. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: Systematic review and meta-analysis. Parkinsonism & Related Disorders. 2016;27:25-34. https://doi.org/10.1016/j.parkreldis.2016.03.002
  56. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology. 2012;79(7):651-658. https://doi.org/10.1212/WNL.0b013e318263570d
  57. Griebel G, Decobert M, Jacquet A, Beeské S. Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats. Behav Brain Res. 2012;232(2):416-420. https://doi.org/10.1016/j.bbr.2012.04.033
  58. Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, Pardi D. Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson Disease. Archives of Neurology. 2008;65(10). https://doi.org/10.1001/archneur.65.10.1337
  59. Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nature and Science of Sleep. 2017;9:39-57. https://doi.org/10.2147/NSS.S103467
  60. Dhuria S, Fine J, Bingham D, Svitak AL, Burns RB, Baillargeon AM, Panter SS, Kazi AN, Frey Ii WH, Hanson LR. Food consumption and activity levels increase in rats following intranasal Hypocretin-1. Neuroscience Letters. 2016;627:155-159. https://doi.org/10.1016/j.neulet.2016.05.053
  61. Kistner A, Lhommée E, Krack P. Mechanisms of Body Weight Fluctuations in Parkinson’s Disease. Frontiers in Neurology. 2014;5:84. https://doi.org/10.3389/fneur.2014.00084
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.